Fate Therapeutics

$61.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.33 (+2.20%) As of 12:43 PM EST today

Why Robinhood?

You can buy or sell FATE and other stocks, options, and ETFs commission-free!

About FATE

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. The listed name for FATE is Fate Therapeutics, Inc. Common Stock.

CEO

J. Scott Wolchko

Employees

178

Headquarters

San Diego, California

Founded

2007

Market Cap

5.40B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

933.83K

High Today

$62.50

Low Today

$60.71

Open Price

$60.71

Volume

174.65K

52 Week High

$62.50

52 Week Low

$13.26

Collections

Analyst Ratings

88%

of 16 ratings

Buy

88%

Hold

13%

Sell

FATE Earnings

-$0.68

-$0.45

-$0.23

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 1, After Hours